Although this patient had low TMB and PD-L1 expression on tumor-infiltrating immune cells was observed, and she harbored a PI3KCA mutation, which could have contributed to the excellent antitumor efficacy of atezolizumab after failure of pembrolizumab. Here, CD274 is linked to neoplasm.